These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 36286921)

  • 1. [Unsolved issues of treatment of adult patients with hemophilia A].
    Zozulya NI; Dimitrieva OS
    Ter Arkh; 2022 Jan; 94(1):77-82. PubMed ID: 36286921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular approaches for improved clotting factors for hemophilia.
    Kaufman RJ; Powell JS
    Blood; 2013 Nov; 122(22):3568-74. PubMed ID: 24065241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence.
    Ghosh K; Ghosh K
    Expert Rev Hematol; 2021 Aug; 14(8):721-730. PubMed ID: 34278926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003429. PubMed ID: 16625581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
    Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pain: a neglected symptom in hemophilia.
    Kurçaloğlu M; Atay MH
    Ann Hematol; 2023 Apr; 102(4):947-953. PubMed ID: 36820905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [NEW INNOVATIONS IN THE TREATMENT OF HEMOPHILIA].
    Levy-Mendelovich S; Brutman-Barazani T; Kenet G
    Harefuah; 2023 Jan; 162(1):47-51. PubMed ID: 36714942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors.
    Leissinger CA; Singleton T; Kruse-Jarres R
    Blood; 2015 Jul; 126(2):153-9. PubMed ID: 25827834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges.
    Trinchero A; Sholzberg M; Matino D
    Hamostaseologie; 2020 Aug; 40(3):311-321. PubMed ID: 32726826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnosis and management of hemophilia].
    Tokugawa T
    Rinsho Ketsueki; 2020; 61(9):1338-1348. PubMed ID: 33162534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients.
    Ar MC; Balkan C; Kavaklı K
    Turk J Haematol; 2019 Aug; 36(3):141-154. PubMed ID: 31088040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting factor replacement therapy in severe hemophilia: which level is important?
    Fischer K; Berntorp E
    Semin Thromb Hemost; 2015 Nov; 41(8):860-3. PubMed ID: 26451746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Articular Bleeding in Hemophilia.
    Rodriguez-Merchan EC
    Cardiovasc Hematol Disord Drug Targets; 2016; 16(1):21-24. PubMed ID: 28049407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophilia A and von Willebrand deficiency: therapeutic implications.
    Basso M; Lazzareschi I; Curatola A; Di Gennaro L; Buonsenso D; Gatto A; De Candia E; De Cristofaro R
    Blood Coagul Fibrinolysis; 2020 Sep; 31(6):397-401. PubMed ID: 32255574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular approaches for improved clotting factors for hemophilia.
    Kaufman RJ; Powell JS
    Hematology Am Soc Hematol Educ Program; 2013; 2013():30-6. PubMed ID: 24319159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High risk and low prevalence diseases: Hemophilia emergencies.
    Alblaihed L; Dubbs SB; Koyfman A; Long B
    Am J Emerg Med; 2022 Jun; 56():21-27. PubMed ID: 35349958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies.
    Teitel JM; Sholzberg M
    Blood Rev; 2013 Mar; 27(2):103-9. PubMed ID: 23452718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hemostatic management of hemophilia].
    Tokugawa T
    Rinsho Ketsueki; 2022; 63(9):1212-1222. PubMed ID: 36198547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.